IP Library › Granted Patent US 12,005,094
Granted Patent B2
US 12,005,094 · App. 17/192,133 · Granted Jun 11, 2024

Inhibitor of inflammatory conditions

Inventors: Emma Jane Blain (Cardiff, GB); Victor Collin Duance (Cardiff, GB); Ahmed Yasine Ali (Swansea, GB); Ifor Delme Bowen (Cardiff, GB)
A61K36/324A61K31/56A61K45/06A61P1/00A61K2236/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,005,094
App. No.
17/192,133
Granted
Jun 11, 2024
Kind
B2
Abstract

The invention relates to Boswellia frereana and particularly an extract of same for treating a range of inflammatory disorder or conditions selected from the group comprising: psoriasis, demyelinating neurological disorders including multiple sclerosis, all forms of muscular dystrophy especially Duchenne muscular dystrophy, sepsis, sepsis syndrome, osteoporosis, ischemic injury, graft vs. host disease, reperfusion injury, asthma, diabetes, cancer, myelogenous and other leukemias, psoriasis and cachexia, Alzheimer's Disease, acetylcholinesterase mediated disorders, retinal disorders, neurological, retinal, and muscular disorders.

Claims (17)

1. A method of treating a disorder or condition selected from the group consisting of: psoriasis, demyelinating neurological disorders including multiple sclerosis, all forms of muscular dystrophy especially Duchenne muscular dystrophy, sepsis, sepsis syndrome, osteoporosis, ischemic injury, graft vs. host disease, reperfusion injury, asthma, diabetes, cancer, myelogenous and other leukemias, cachexia, Alzheimer's Disease, acetylcholinesterase mediated disorders, retinal disorders, neurological disorders, muscular disorders, and a combination thereof in a patient in need thereof, comprising administering to said patient an effective amount of an alcohol extract of Boswellia frereana , wherein said extract comprises epi-lupeol or a salt thereof, and wherein the extract is devoid of boswellic acids.

2. The method of claim 1 , wherein said extract comprises one or more of the following: β-amyrin, α-amyrin, α-phellandrene dimers, α-thujene, and α-phellandrene, and isomers or salts thereof.

3. The method of claim 1 , wherein said extract comprises one or more of the following: β-amyrin, α-phellandrene dimers, and isomers or salts thereof.

4. The method of claim 1 , wherein said extract is a methanol extract.

5. The method of claim 1 , wherein said extract is an ethanol extract.

6. The method of claim 1 , wherein the muscular dystrophy is Duchenne muscular dystrophy.

7. A method of treating a disorder or condition selected from the group consisting of: psoriasis, demyelinating neurological disorders including multiple sclerosis, all forms of muscular dystrophy, sepsis, sepsis syndrome, osteoporosis, ischemic injury, graft vs. host disease, reperfusion injury, asthma, diabetes, cancer, myelogenous and other leukemias, cachexia, Alzheimer's Disease, acetylcholinesterase mediated disorders, retinal disorders, neurological disorders, muscular disorders, and a combination thereof in a patient in need thereof, comprising administering to said patient:

a. an effective amount of an alcohol extract of Boswellia frereana , wherein said extract comprises epi-lupeol or a salt thereof, and wherein the extract is devoid of boswellic acids;

b. a composition comprising an effective amount of an alcohol extract of Boswellia frereana , wherein said extract comprises epi-lupeol or a salt thereof, and wherein the extract is devoid of boswellic acids; or

c. a combination therapeutic comprising:

i.) an effective amount of an alcohol extract of Boswellia frereana , wherein said extract comprises epi-lupeol or a salt thereof, and wherein the extract is devoid of boswellic acids; and

ii.) an additional therapeutic.

8. The method of claim 7 , wherein said extract comprises one or more of the following: β-amyrin, α-amyrin, α-phellandrene dimers, α-thujene, and α-phellandrene, and isomers or salts thereof.

9. The method of claim 7 , wherein said extract comprises one or more of the following: β-amyrin, α-phellandrene dimers, and isomers or salts thereof.

10. The method of claim 7 , wherein said extract is a methanol extract.

11. The method of claim 7 , wherein said extract is an ethanol extract.

12. The method of claim 7 , wherein the muscular dystrophy is Duchenne muscular dystrophy.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2021
From: BLAIN, EMMA JANE; DUANCE, VICTOR COLLIN; ALI, AHMED YASINE; BOWEN, IFOR DELME
To: COMPTON DEVELOPMENTS LTD.
Reel/Frame 055695/0139 →
Priority Claims (2)
GB 0912526 · Jul 18, 2009 · national
GB 0921086 · Dec 2, 2009 · national
Continuity (3)
Continuation In Part 15227054 · Aug 3, 2016
Continuation In Part 13384645
Related Publication 20210213088A1 · Jul 15, 2021